Windlas Biotech IPO subscribed 22 41 times business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
NEW DELHI: Analysts tracking primary issues believe one can subscribe to the initial public offering of Windlas Biotech, a Contract Development Manufacturing Organisation (CDMO), for the long term. The issue opens for subscription today.
The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS). The price band for the issue is fixed at Rs 448-460 per share.
“Windlas is focusing on formulation CDMO, and there is no peer company focusing solely on the CDMO model. Considering its return ratios and profitability, the issue seems to be fully priced. But factoring the growth drivers of the CDMO sector and opportunities available for the company, we assign a ‘subscribe for long term’ rating on the issue,” said Rajnath Yadav of Choice Broking.
4 IPOs open on Aug 4: Krsnaa Diagnostics, Windlas Biotech, Devyani International and Exxar Tiles
Four IPOs will open for subscription on Wednesday (August 4). These include initial public offerings (IPOs) of Windlas Biotech, Devyani International, Krsnaa Diagnostics and Exxaro Tiles. Buoyed by bumper listings of Clean Science and Technology, GR Infraprojects, Zomato and Tatva Chintan Pharma Chem on the bourses, the four firms are expecting for their turn to make a strong debut on the Dalal Street.
Let s take a look at four IPOs that will open for subscription this week:Â
Krsnaa Diagnostics IPO: Aug 4 to 6; price band Rs 933-954
Krsnaa Diagnostics said it has fixed a price band of Rs 933-954 a share for its little over Rs 1,213 crore initial share-sale. The three-day IPO will open for public subscription on August 4 and conclude on August 6. The IPO comprises fresh issue of equity shares worth Rs 400 crore and an offer for sale (OFS) of up to 8,525,520 equity stocks by its exis